View Older Stories View More Recent Stories

Jul 11, 2017 07:22PM FDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children
Jul 11, 2017 04:00PM Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket
Jun 29, 2017 05:31PM Amgen (AMGN) Announces FDA Approval for Vectibix For Use In Wild-Type RAS Metastatic Colorectal Cancer
Jun 29, 2017 05:30PM FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer
Jun 23, 2017 04:02PM Amgen (AMGN) Announces Positive CHMP Opinion To Expand Use of Mimpara to Treat Secondary HPT in Certain Children
Jun 23, 2017 04:00PM Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
Jun 21, 2017 09:00AM Amgen To Present New Data At 22nd Congress of the European Hematology Association
Jun 19, 2017 09:02AM Amgen (AMGN) Confirms FDA Acceptance of Supplemental Biologics License Application To Expand Indication For XGEVA (denosumab) To Include Multiple Myeloma Patients
Jun 19, 2017 09:00AM FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients
Jun 8, 2017 04:33PM Amgen (AMGN) Presents Erenumab Data at AHS
Jun 8, 2017 04:30PM Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society
Jun 8, 2017 04:00PM Amgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference
Jun 7, 2017 09:01AM Amgen (AMGN) & Allergan (AGN) Reports FDA Advisory Committee Meeting To Review ABP 215 (Biosimilar Candidate To Bevacizumab)
Jun 7, 2017 09:00AM Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
Jun 5, 2017 09:06AM Amgen (AMGN) Submits Regulatory Applications For Repatha Cardiovascular Outcomes Data in US And Europe
Jun 5, 2017 09:00AM Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe
Jun 5, 2017 06:30AM Amgen (AMGN) Reports New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO Meetings
Jun 5, 2017 06:06AM Amgen (AMGN) Announces New Phase 2 Data On IMLYGIC (Talimogene Laherparepvec) Investigational Combination At ASCO Meetings
Jun 4, 2017 10:45AM Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Jun 3, 2017 05:45PM Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
Jun 2, 2017 04:00PM Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge
May 22, 2017 06:01AM Amgen (AMGN) Announces New on Repatha® (Evolocumab) for Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets
May 22, 2017 05:56AM Amgen (AMGN) & UCB Report Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY (Romosozumab)
May 21, 2017 06:01PM Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis
May 20, 2017 03:05PM Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets
May 19, 2017 05:06PM Amgen Announces Voting Results of Annual Meeting of Stockholders
May 18, 2017 09:03AM Amgen (AMGN) Submits BLA for Erenumab to FDA
May 18, 2017 09:00AM Amgen Submits Biologics License Application To The FDA For Erenumab
May 17, 2017 05:00PM Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
May 12, 2017 04:00PM Amgen To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference
May 2, 2017 05:15PM Amgen (AMGN) Announces Cardiovascular Outcomes-Based Refund Contract with Harvard Pilgrim for Repatha (Evolocumab)
May 2, 2017 04:00PM Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab)
Apr 27, 2017 04:00PM Amgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease
Apr 26, 2017 04:04PM Amgen Reports First Quarter 2017 Financial Results
Apr 24, 2017 04:33PM Amgen (AMGN), Novartis (NVS) Expand Commercial Collaboration for Erenumab In Migraine
Apr 24, 2017 04:30PM Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine
Apr 21, 2017 04:00PM Amgen Announces Webcast Of 2017 First Quarter Financial Results
Apr 18, 2017 04:02PM Amgen (AMGN) Launches Neulasta Onpro NARRATIVES
Apr 18, 2017 04:00PM Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES
Apr 4, 2017 09:08AM Amgen (AMGN) Submits Applications in US, Europe to Expand Indication For XGEVA to Include Patients With Multiple Myeloma
Apr 4, 2017 09:00AM Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma
Apr 3, 2017 06:24AM Amgen (AMGN), UCB Phase 2 Study of EVENITY Shows Second Course Led to Significant Increases in Bone Mineral Density
Apr 1, 2017 11:30AM Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)
Mar 29, 2017 04:10PM Amgen (AMGN) Receives Priority Review for BLINCYTO® (blinatumomab) Supplemental Biologics License Application from FDA
Mar 29, 2017 04:07PM FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application
Mar 29, 2017 04:06PM Amgen (AMGN) Reports Published Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Mar 29, 2017 04:03PM Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Mar 28, 2017 09:00AM Amgen Awards Three Golden Tickets for LabCentral Residency
Mar 23, 2017 04:01PM Amgen (AMGN) Reports EC Approval for AMGEVITA to Treat Certain Inflammatory Diseases
Mar 23, 2017 04:00PM European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
View More Recent Stories View Older Stories